Loading cancer entity…
Loading cancer entity…
Clinical trials
231 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03220009 | Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 3, 2018 | clinicaltrials |
Data updated 22 days agoSource updated Oct 3, 2018source: clinicaltrials